Document is current
Any future updates will be listed below
-
Authors
Rizk, Elsie
Tajchman, Sharla
Fink, Ezekiel
Aryal, Dipendra K.
Iso, Tomona
Flores, Eleazar
Brown, Anthony E.
Chokshi, Sagar P.
Desai, Shetal-Nicholas
Dewan, Ashvin K.
Kazzaz, Sarah A.
Guevara, Myriam
Nagaraj, Sudha
Robben, Christopher P.
Vittone, Veronica
Swan, Joshua T.
-
Funding
Funding for this research was provided by:
Pfizer
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 23 January 2023
Accepted: 14 June 2023
First Online: 30 June 2023
Declarations
:
: The Houston Methodist Research Institute’s Institutional Review Board approved this study with a waiver of informed consent (approval number PRO00024493). All study methods were carried out in accordance with the relevant guidelines and regulations including the Declaration of Helsinki.
: Not applicable.
: This study was sponsored by Pfizer and Eli Lilly & Company. Joshua Swan is an employee of Houston Methodist Hospital, which received funding from Pfizer and Eli Lilly & Company in connection with this study and the development of this manuscript. Dr. Swan’s employer (Houston Methodist) has received funding on his behalf for analgesia research from Pacira Pharmaceuticals, Inc and Heron Therapeutics. Co-author Sharla Tajchman, who is an employee at Pfizer with stock and/or stock options, participated in study design, interpretation of study data, and writing of the manuscript. All remaining authors declare no conflict of interest
